Arix Bioscience PLC has released its unaudited estimated Net Asset Value (NAV) for November 2023. The NAV breakdown for the date ended 30 November 2023 is as follows: Total NAV of £54.3 million, with a NAV per share of £1.77. The breakdown includes a Listed Portfolio valued at £66.4 million, an Unlisted Portfolio valued at £105.8 million, Cash of £2.6 million, and Other Interests valued at £229.1 million. Arix Bioscience is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies. They collaborate with exceptional entrepreneurs and provide capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. Arix Bioscience is listed on the London Stock Exchange.